Overview

3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with 3-AP in treating patients who have metastatic non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Vion Pharmaceuticals
Treatments:
Gemcitabine